Taysha Gene Therapies
Quarterly Financials
| Values in thousands | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 |
|---|---|---|---|---|
Revenue | $5,485 | $0 | $1,986 | $2,302 |
Gross Profit | 5,186 | -286 | 1,986 | 2,302 |
EBITDA | -28,001 | -32,431 | -26,588 | -21,227 |
EBIT | -28,300 | -32,717 | -26,865 | -21,510 |
Net Income | -27,851 | -32,732 | -26,882 | -21,529 |
Net Change In Cash | 5,485 | 0 | 1,986 | 2,302 |
Free Cash Flow | -26,972 | -24,274 | -20,184 | -22,398 |
Cash | 319,767 | 297,344 | 312,761 | 116,593 |
Basic Shares | 319,711 | 353,309 | 297,988 | 269,306 |
Annual Financials
| Values in thousands | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
Revenue | $9,773 | $8,333 | $15,451 | $2,502 |
Gross Profit | 8,628 | 8,333 | 15,451 | 14 |
EBITDA | -109,353 | -87,951 | -105,197 | -159,729 |
EBIT | -110,498 | -89,196 | -106,568 | -162,216 |
Net Income | -108,995 | -89,298 | -111,566 | -166,014 |
Net Change In Cash | 9,773 | 8,333 | 15,451 | 2,502 |
Free Cash Flow | -93,828 | -81,599 | -80,387 | -113,259 |
Cash | 319,767 | 139,036 | 143,940 | 87,880 |
Basic Shares | 319,711 | 250,134 | 116,121 | 43,952 |
Earnings Calls
| Quarter | EPS |
|---|---|
2026-03-31 | $0 |
2025-12-31 | -$0.07 |
2025-09-30 | -$0.08 |
2025-06-30 | -$0.08 |
